Vicapsys Life Sciences, Inc.
VICP
Rank in Stocks
#26897
Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive... Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive VICAPSYN product to market, guiding it through development and commercialization. This product's intended application is within the field of transplantation, specifically for various transplant therapies and associated stem-cell uses. Additionally, the company is advancing the development of VYBRIN, a compound based on CXCL12. VYBRIN is being investigated for multiple purposes: preventing the formation of post-surgical adhesions following abdominal operations, coating implantable medical devices and other implants to inhibit fibrosis, and promoting wound healing, with a particular emphasis on diabetic ulcers. The firm, originally incorporated in 1997, transitioned its name from Phage Therapeutics International, Inc. to Vicapsys Life Sciences, Inc. in September 2017. Its operations are headquartered in Suwanee, Georgia.
Share Price
$0.5
Last synced: 2026-11-09
Market Cap
$17.69M
Change (1 day)
0.00%
Change (1 year)
-66.67%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Vicapsys Life Sciences, Inc. (VICP)
Category
Healthcare
Operating Margin for Vicapsys Life Sciences, Inc. (VICP)
Operating Margin as of November 2026 TTM: 0.00%
According to Vicapsys Life Sciences, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Vicapsys Life Sciences, Inc. from 2008 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | -100.00% |
| 2009 | -17.39% | -49.87% |
| 2008 | -34.69% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Vicapsys Life Sciences, Inc.'s operating margin
What was Vicapsys Life Sciences, Inc.'s operating margin in 2025?
In 2025, Vicapsys Life Sciences, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Vicapsys Life Sciences, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Vicapsys Life Sciences, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does Vicapsys Life Sciences, Inc.'s operating margin compare with similar companies?
Vicapsys Life Sciences, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.